

# Meningococcal Vaccines—High-risk Populations

Different vaccines protect against different serogroups.

**Risk groups:**

- Exp.** Increased Exposure to meningococcal serogroups covered by vaccines (due to outbreaks<sup>1</sup>, travel to affected areas [e.g. the Hajj], lab exposure)
- CD.** Persistent Complement component Deficiencies (including persons taking eculizumab [Soliris<sup>®</sup>])
- Asp.** Functional or Anatomic Asplenia (including sickle cell disease)
- HIV.** HIV Infection

Age at first dose	Exp	CD	Asp	HIV	1) MenACWY vaccines <sup>2</sup>	Boosters for those who remain at increased risk <sup>7</sup>												
2–6 months	✓	✓	✓	✓	2 months: ACWY-CRM Menveo <sup>®</sup> 4 months: ACWY-CRM Menveo <sup>®</sup> 6 months: ACWY-CRM Menveo <sup>®</sup> 12–15 months: ACWY-CRM <sup>3</sup> Menveo <sup>®</sup>	If primary dose(s) given when younger than 7 years: 3 years → ACWY-CRM or -D <sup>6</sup> Menveo <sup>®</sup> or Menactra <sup>®</sup> → Every 5 years → ACWY-CRM or -D Menveo <sup>®</sup> or Menactra <sup>®</sup>												
7–23 months	✓	✓	✓	✓	ACWY-CRM Menveo <sup>®</sup> → 3 months → ACWY-CRM <sup>3</sup> Menveo <sup>®</sup>													
9–23 months	✓	✓			ACWY-D <sup>4,5,6</sup> Menactra <sup>®</sup> → 3 months → ACWY-D <sup>3,6</sup> Menactra <sup>®</sup>													
2 years and older		✓	✓ <sup>5</sup>	✓ <sup>5</sup>	ACWY-CRM or -D <sup>5,6</sup> Menveo <sup>®</sup> or Menactra <sup>®</sup> → 2 months → ACWY-CRM or -D <sup>6</sup> Menveo <sup>®</sup> or Menactra <sup>®</sup>		If primary dose(s) given at age 7 years or older: Every 5 years → ACWY-CRM or -D Menveo <sup>®</sup> or Menactra <sup>®</sup>											
		✓			ACWY-CRM or -D <sup>5,6</sup> Menveo <sup>®</sup> or Menactra <sup>®</sup>													
<b>2) Also give MenB vaccine—may be given at same time as MenACWY vaccine. Use the same brand for each dose in the series.</b>																		
10 years and older	✓	✓	✓		1st dose: MenB-4C Bexsero <sup>®</sup> → 1 month → 2nd dose: MenB-4C Bexsero <sup>®</sup> <b>OR</b> 1st dose: MenB-FHbp Trumenba <sup>®</sup> → 1–2 months → 2nd dose: MenB-FHbp Trumenba <sup>®</sup> → 6 months between 1st and 3rd dose → 3rd dose: MenB-FHbp Trumenba <sup>®</sup>	<table border="1"> <thead> <tr> <th>Exp</th> <th>CD</th> <th>Asp</th> <th>Boosters</th> </tr> </thead> <tbody> <tr> <td>lab</td> <td>✓</td> <td>✓</td> <td>                             Lab exposure, complement deficiency, asplenia:                              1 year → MenB → Every 2–3 years → MenB                         </td> </tr> <tr> <td>out-break</td> <td></td> <td></td> <td>                             Increased risk during an outbreak:                              1+ years → MenB (Interval of ≥6 months may be considered depending on the outbreak.)                         </td> </tr> </tbody> </table>	Exp	CD	Asp	Boosters	lab	✓	✓	Lab exposure, complement deficiency, asplenia: 1 year → MenB → Every 2–3 years → MenB	out-break			Increased risk during an outbreak: 1+ years → MenB (Interval of ≥6 months may be considered depending on the outbreak.)
					Exp		CD	Asp	Boosters									
lab	✓	✓	Lab exposure, complement deficiency, asplenia: 1 year → MenB → Every 2–3 years → MenB															
out-break			Increased risk during an outbreak: 1+ years → MenB (Interval of ≥6 months may be considered depending on the outbreak.)															

For further details, see [www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html). For routine use, see [EZIZ.org/assets/docs/IMM-1217.pdf](http://EZIZ.org/assets/docs/IMM-1217.pdf).

- Information on outbreaks at <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx>
  - Abbreviations: ACWY/ACWY-CRM/ACWY-D = MenACWY = MCV4
  - Minimum age 12 months.
  - MenACWY-D (Menactra<sup>®</sup>) is licensed starting at 9 months.
  - If MenACWY-D (Menactra<sup>®</sup>) is used for persons with asplenia or HIV infection, defer until age 2 years and at least 4 weeks after completion of PCV13 series.
  - It is recommended that MenACWY-D be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.
  - If no longer at high risk by age 10, administer additional two doses of MenACWY according to the regular adolescent schedule at age 11–12 years and age 16 years.
- This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC)



California Department of  
Public Health  
Immunization Branch

EZIZ.org IMM-1218 (2/20)